Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 17/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3198364 | 1.00 | MAOA (0.66) | MAOACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3198387 | 1.00 | MAOA (0.66) | MAOACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3198375 | 1.00 | MAOA (0.66) | MAOACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13484629 | 0.92 | MAOA (0.55) | MAOACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3194183 | 0.90 | CALML3 (0.50) | MAOACYP3A4CYP2C9 | |
| SCHEMBL13484649 | 0.90 | CALML3 (0.50) | MAOACYP3A4CYP2C9 | |
| SCHEMBL13484630 | 0.90 | MAOA (0.60) | MAOACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3205880 | 0.86 | MAOA (0.48) | MAOACYP3A4 | |
| SCHEMBL3205876 | 0.86 | MAOA (0.48) | MAOACYP3A4 | |
| SCHEMBL3203213 | 0.83 | CHRM1 (0.55) | MAOACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254892-B1 | BICYCLIC NITROIMIDAZOLES COVALENTLY LINKED TO SUBSTITUTED PHENYL OXAZOLIDINONES | GLOBAL ALLIANCE FOR TB DRUG DEV (US) | 2014-04-23 | — | — | EP | claimed |
| US-7666864-B2 | Bicyclic nitroimidazole-substituted phenyl oxazolidinones | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2010-02-23 | — | — | US | claimed |
| US-20090281088-A1 | BICYCLIC NITROIMIDAZOLE-SUBSTITUTED PHENYL OXAZOLIDINONES | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2009-11-12 | — | — | US | claimed |
| US-7666864-B2 | Bicyclic nitroimidazole-substituted phenyl oxazolidinones | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090281088-A1 | BICYCLIC NITROIMIDAZOLE-SUBSTITUTED PHENYL OXAZOLIDINONES | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281088-A1 | BICYCLIC NITROIMIDAZOLE-SUBSTITUTED PHENYL OXAZOLIDINONES | O60361, OXA1L, TBCD | MAOA 2050/4885CYP3A4 564/4885CYP2D6 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.